Pfizer Inc
-
Open
36.67
-
Previous Close
36.63
-
Volume (Avg)
13.00M (24.53M)
-
Day's Range
36.60-36.89
-
52Wk Range
31.67-39.43
-
Market Cap.
217.90B
-
Dividend Rate (Yield)
1.36 (3.71%)
-
Beta
0.90
-
Shares Outstanding
5.95B
-
P/E Ratio (EPS)
10.41 (3.52)
Top Stories
-
BRIEF-Pfizer: EU Approves Mylotarg With Chemotherapy To Treat Acute Myeloid Leukemia
Reuters 52 mins agoApril 23 (Reuters) - Pfizer Inc: * MYLOTARG™ APPROVED IN THE EU FOR THE TREATMENT OF PREVIOUSLY UNTREATED, DE NOVO, CD33-POSITIVE ACUTE MYELOID LEUKEMIA IN COMBINATION WITH CHEMOTHERAPY * PFIZER - APPROVAL OF MYLOTARG BASED ON DATA FROM INVESTIGATOR-LED ...
-
FDA declines to approve Pfizer biosimilar of Roche's cancer drug
Reuters -
BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar
Reuters -
Pfizer's Mylotarg OK'd in Europe for certain type of AML
Seeking Alpha -
FDA rejects Pfizer's application for Herceptin biosimilar
Seeking Alpha 6 hrs agoCiting the need for additional technical information, the FDA issues a Complete Response Letter (CRL) to Pfizer (PFE +0.4%) regarding its marketing application seeking approval for a biosimilar of Roche's (OTCQX:RHHBY) Herceptin (trastuzumab). The company ...
-
FDA declines to approve Pfizer's biosimilar to Roche's cancer drug
Reuters -
Pfizer says FDA failed to approve Herceptin biosimilar
MarketWatch -
Pfizer: EU Approves Mylotarg In Combination With Chemotherapy To Treat AML
Nasdaq -
Pfizer (PFE) Announces MYLOTARG Was Approved in EU For Treatment Of Previously Untreated, De Novo, CD33-positive AML in Combination With Chemotherapy
StreetInsider -
Pfizer Receives CRL On Trastuzumab Biosimilar
Nasdaq -
Pfizer : Explore New Strategies to Maintain a Global Pharmacovigilance System by Pfizer at SMi’s 5th Drug Safety Conference
4-Traders -
Pfizer : Portage slashes taxes for Pfizer expansion expected to add 450 jobs
4-Traders -
Ocular Implants Market Report 2018-2025: Alcon, Bausch & Lomb Incorporated, Pfizer, Morcher, STAAR Surgical
Digital Journal -
Private Equity Jobs of the Week: FT Partners, KeyBank, Pfizer are hiring
PE Hub -
FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info
FiercePharma 3 hrs agoPfizer is no stranger to biosimilar setbacks, and the company suffered another on Monday with the FDA's decision to turn away its application for a knockoff of Roche's Herceptin. The FDA issued a Complete Response Letter seeking "additional technical ...
-
Pfizer's Herceptin copy hits FDA roadblock
BioPharma Dive -
Pfizer's first U.K. ads for OTC Viagra put erectile dysfunction in perspective
FiercePharma -
Pharmalittle: Fresenius walks away from Akorn deal; FDA bounces a Pfizer biosimilar
STAT
